However, the power of PROTACs lies in the engagement of E3 ligases, and currently, less than two percent of the vast array of E3 ligases in the human genome have been explored in the TPD field. Dr.

UK-based biotech company Outrun Therapeutics has announced its launch with a $10m seed investment to advance its protein stabilisation pipeline focused on E3 ligase inhibitors. The financial ...

During ubiquitination, a group of enzymes called E3 ubiquitin ligases attach a small protein called ubiquitin to other proteins. This tagging, in turn, helps determine the fate of the targeted ...

Herbicide development has slowed in recent years, but innovative research methods could soon drive significant progress in ...

Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Market Capitalization Perspectives: The company's market ...

DUNDEE, Scotland, Jan. 13, 2025 /PRNewswire/ -- Outrun Therapeutics ("Outrun"), the E3 ligase inhibitor and protein stabilisation specialist, today announces the appointment of Matthew Fyfe as its ...

Nurix Therapeutics (NRIX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...

I am excited to be able to leverage my knowledge and experience in drug discovery and development alongside the world-leading E3 ligase expertise offered by the Outrun team and its academic ...